FDA Approval Of Gilead’s Sofosbuvir Shows Flexibility On HCV Combos
Pricing means an $84,000 cost of therapy for some HCV patients, but $168,000 for others. The nucleotide polymerase inhibitor will be dosed with ribavirin but eliminates interferon for patients with genotypes 2 and 3, making it the first all-oral therapeutic regimen.
You may also be interested in...
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.